Literature DB >> 25544128

R0 resection, not surgical technique, is the key consideration in pelvic exenteration surgery.

O J Warren1, M J Solomon.   

Abstract

Mesh:

Year:  2014        PMID: 25544128     DOI: 10.1007/s10151-014-1256-3

Source DB:  PubMed          Journal:  Tech Coloproctol        ISSN: 1123-6337            Impact factor:   3.781


× No keyword cloud information.
  5 in total

1.  Extended lateral pelvic sidewall excision (ELSiE): an approach to optimize complete resection rates in locally advanced or recurrent anorectal cancer involving the pelvic sidewall.

Authors:  I Shaikh; W Aston; G Hellawell; D Ross; S Littler; D Burling; M Marshall; J M A Northover; A Antoniou; J T Jenkins
Journal:  Tech Coloproctol       Date:  2014-11-08       Impact factor: 3.781

2.  Meta-analysis of survival based on resection margin status following surgery for recurrent rectal cancer.

Authors:  A Bhangu; S M Ali; A Darzi; G Brown; P Tekkis
Journal:  Colorectal Dis       Date:  2012-12       Impact factor: 3.788

3.  Pelvic exenteration with en bloc iliac vessel resection for lateral pelvic wall involvement.

Authors:  Kirk K S Austin; Michael J Solomon
Journal:  Dis Colon Rectum       Date:  2009-07       Impact factor: 4.585

4.  Quality of life and other patient-reported outcomes following exenteration for pelvic malignancy.

Authors:  J M Young; T Badgery-Parker; L M Masya; M King; C Koh; A C Lynch; A G Heriot; M J Solomon
Journal:  Br J Surg       Date:  2014-01-13       Impact factor: 6.939

5.  Sacral resection with pelvic exenteration for advanced primary and recurrent pelvic cancer: a single-institution experience of 100 sacrectomies.

Authors:  Tony Milne; Michael J Solomon; Peter Lee; Jane M Young; Paul Stalley; James D Harrison; Kirk K S Austin
Journal:  Dis Colon Rectum       Date:  2014-10       Impact factor: 4.585

  5 in total
  1 in total

Review 1.  Surgical treatment of locally recurrent rectal cancer: a narrative review.

Authors:  Zhaoya Gao; Jin Gu
Journal:  Ann Transl Med       Date:  2021-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.